How to Get Enclomiphene Citrate in New York

What Is Enclomiphene Citrate and Why Do New York Men Seek It?

Enclomiphene citrate is the trans-isomer of clomiphene, a selective estrogen receptor modulator (SERM) that stimulates the hypothalamic-pituitary axis to increase endogenous luteinizing hormone (LH) and follicle-stimulating hormone (FSH), which then drives testicular testosterone production. Unlike exogenous testosterone replacement therapy (TRT), enclomiphene preserves spermatogenesis, making it the preferred option for men with secondary hypogonadism who want to maintain fertility [1].

New York has one of the highest concentrations of men aged 30 to 55 seeking hypogonadism treatment in the United States, and secondary hypogonadism, where testosterone is low because the pituitary is under-signaling rather than the testes failing, accounts for approximately 40% of male hypogonadism cases seen in outpatient endocrinology [2]. The Endocrine Society's 2018 Clinical Practice Guideline defines secondary hypogonadism as serum total testosterone below 300 ng/dL on two morning measurements combined with elevated or inappropriately normal LH and FSH [3].

Enclomiphene is not FDA-approved as a standalone drug (Androxal, its brand-name IND, was withdrawn before final approval), so all U.S. supply is currently compounded by licensed 503A or 503B pharmacies [4]. In New York, 503A pharmacies are regulated by the New York State Board of Pharmacy under Education Law Article 137, and they may legally compound enclomiphene citrate for individual patient prescriptions written by licensed New York prescribers [5].

Kim et al. (BJU Int, 2016, N=124) demonstrated that enclomiphene 12.5 mg and 25 mg daily normalized serum testosterone in 76% of men with secondary hypogonadism at 24 weeks while preserving sperm counts, compared to TRT, which suppressed sperm concentration by more than 90% in the same trial [1]. That fertility-preservation profile is the main clinical reason New York prescribers reach for enclomiphene over testosterone cypionate for younger men.

How to Get an Enclomiphene Prescription in New York: Step-by-Step

Getting a prescription follows a predictable four-step path in New York. Order baseline labs, complete a clinical consultation, receive the prescription, and choose a pharmacy.

Step 1: Order or retrieve your baseline labs. New York-licensed telehealth providers can order labs electronically to any Quest Diagnostics or LabCorp draw site in New York before your first appointment. You need at minimum: total testosterone (two morning draws, collected before 10 a.m.), free testosterone (calculated or equilibrium dialysis), LH, FSH, estradiol, sex hormone-binding globulin (SHBG), complete blood count (CBC), comprehensive metabolic panel (CMP), and a fasting lipid panel [3]. Some providers also require a prolactin level to rule out pituitary adenoma before starting a SERM [6].

Step 2: Complete a telehealth or in-person clinical consultation. New York's telehealth prescribing law (Public Health Law Section 2999-cc) permits a prescriber to conduct an initial evaluation via real-time two-way audio/video and issue a prescription for a compounded drug without a prior in-person visit, provided the standard of care is met [7]. The consultation typically runs 20 to 40 minutes. The clinician reviews lab values, symptoms, medical history, and contraindications including personal or family history of blood clots, estrogen-sensitive tumors, or severe liver disease.

Step 3: Receive the electronic prescription. New York prescribers transmit the prescription electronically to a patient-designated 503A compounding pharmacy. New York State requires all controlled substance prescriptions to use the I-STOP electronic prescribing system, but enclomiphene is not a controlled substance, so standard e-prescribing platforms suffice [8].

Step 4: Pharmacy compounds and ships. A registered 503A pharmacy compounds the capsules or tablets to the prescribed strength, typically 12.5 mg or 25 mg, and ships via USPS or UPS to the patient's New York address. Standard turnaround is 3 to 5 business days after the prescription is received.

What Labs Are Required Before Enclomiphene Citrate in New York?

A prescriber cannot safely initiate enclomiphene without confirming secondary hypogonadism biochemically. Low testosterone alone does not justify a SERM.

The minimum required panel, per Endocrine Society 2018 guidelines, is [3]:

• Total testosterone: Two fasting, morning draws on separate days showing values below 300 ng/dL
• LH and FSH: Must be low or inappropriately normal (not elevated) to confirm secondary rather than primary hypogonadism
• Estradiol (E2): Baseline needed to monitor for SERM-driven estrogen elevation; men with baseline E2 above 40 pg/mL may need adjunct aromatase inhibitor therapy [9]
• SHBG: Affects free testosterone calculation; elevated SHBG (above 50 nmol/L) is common in men over 50 and shifts clinical interpretation
• CBC: Enclomiphene-driven testosterone increases can raise hemoglobin and hematocrit; baseline hematocrit above 54% is a contraindication [3]
• CMP and lipid panel: SERMs can affect lipid metabolism and liver enzymes; a 2019 analysis in the Journal of Clinical Endocrinology and Metabolism noted small but statistically significant HDL reductions with clomiphene-class agents in men [10]
• Prolactin: A single elevated prolactin reading can indicate a pituitary adenoma, which would require MRI before SERM therapy [6]

Most New York telehealth providers will not issue a prescription without all seven panels completed and reviewed. Lab results older than 90 days are typically not accepted.

Telehealth Providers in New York Prescribing Enclomiphene Citrate

New York residents have access to several categories of telehealth providers for enclomiphene prescriptions.

Dedicated hormone-therapy telehealth platforms operate fully within New York and hold state-specific provider licenses. These platforms pair patients with MDs, DOs, NPs, or PAs who specialize in men's health endocrinology. Visits are conducted via HIPAA-compliant video platforms. Prescriptions are transmitted within 24 to 72 hours of the consultation if labs are in range.

Endocrinologists and urologists in New York increasingly offer telehealth follow-up after an initial in-person visit. The NYU Langone Endocrinology and the Weill Cornell Men's Health program both see patients with secondary hypogonadism, though wait times for in-person new-patient appointments can run 4 to 12 weeks. Telehealth-first platforms generally have faster access.

Primary care physicians licensed in New York may prescribe enclomiphene off-label if they are comfortable interpreting the lab panel and managing SERM therapy. The American Urological Association 2018 guideline on male hypogonadism notes that off-label SERM use is medically supported but should be accompanied by documented informed consent regarding the compounded and off-label status of the drug [11].

New York law allows nurse practitioners (NPs) with full practice authority (FPA) and physician assistants (PAs) working under a collaborative agreement to prescribe enclomiphene. New York granted NPs full practice authority in 2023 for those with more than 3 to 600 hours of clinical experience, expanding the prescriber pool considerably [12].

The table below shows the HealthRX clinical decision framework used by our reviewing physicians to determine whether a New York patient qualifies for enclomiphene versus testosterone replacement or watchful waiting:

| Testosterone (ng/dL) | LH/FSH | Fertility Goal | Preferred Agent | |---|---|---|---| | <300, two draws | Low or normal | Yes | Enclomiphene 12.5-25 mg/day | | <300, two draws | Low or normal | No | Testosterone cypionate or enanthate | | <300, two draws | Elevated | Any | Refer to urology (primary hypogonadism) | | 300-400, symptomatic | Low or normal | Yes | Consider enclomiphene trial with 90-day recheck | | >400 | Any | Any | Watchful waiting; treat contributing conditions |

503A Compounding Pharmacies in New York for Enclomiphene Citrate

New York-licensed 503A pharmacies can legally compound enclomiphene citrate for individual patient prescriptions. All 503A pharmacies in New York must be registered with the New York State Board of Pharmacy and comply with USP <795> standards for non-sterile compounding, which govern ingredient quality, stability testing, and labeling [5].

Key facts about 503A compounding in New York:

Ingredient sourcing. 503A pharmacies must use active pharmaceutical ingredients (APIs) from FDA-registered facilities. Enclomiphene citrate API is available from several FDA-registered foreign and domestic manufacturers. The FDA's Compounding Compliance Policy Guide requires pharmacies to obtain a certificate of analysis for each lot [4].

Permitted dose forms. New York 503A pharmacies compound enclomiphene as oral capsules (most common) or sublingual troches. Typical strengths are 12.5 mg and 25 mg per unit.

Shipping. 503A pharmacies may ship to patients anywhere within New York State on receipt of a valid prescription. Interstate shipping requires the pharmacy to hold a non-resident pharmacy license in both the originating and receiving states; if using a pharmacy headquartered outside New York, confirm they hold a New York non-resident pharmacy registration before filling [5].

Quality verification. Patients can request a certificate of analysis (CoA) from any 503A pharmacy showing the enclomiphene content, potency, and sterility or particulate testing results. Reputable pharmacies provide this with every shipment.

A 2021 JAMA Internal Medicine analysis found that compounded testosterone products from 503A pharmacies showed potency variation of 12% to 32% from labeled dose across 45 sampled products; while that study focused on testosterone, it underscores the importance of requesting CoA documentation for any compounded hormone product [13].

New York Medicaid and Insurance Coverage for Enclomiphene Citrate

New York Medicaid covers enclomiphene citrate for secondary hypogonadism with prior authorization (PA). Because the drug is off-label and compounded, the PA process requires specific documentation.

Required PA documentation in New York:

1. Diagnosis code: E23.0 (hypopituitarism) or E29.1 (testicular hypofunction) with documentation supporting secondary etiology
2. Two testosterone lab results below 300 ng/dL with date stamps
3. LH and FSH results confirming central (secondary) rather than primary hypogonadism
4. Documentation that at least one FDA-approved agent was either tried and failed or is contraindicated (for most plans, this means noting why testosterone TRT is not preferred, such as fertility preservation needs)
5. Prescriber attestation of medical necessity
6. Prescription from a New York-licensed prescriber

New York Medicaid PA requests are submitted through the eMedNY system and typically receive a determination within 3 to 5 business days for standard requests. Expedited PA (24-hour review) is available when the prescriber documents that a standard timeline would "seriously jeopardize the patient's life or health" per 42 CFR 438.210 [14].

Private commercial insurers in New York, including Empire BlueCross, MVP Health Care, and Healthfirst, vary widely in coverage. Most classify compounded enclomiphene as a non-covered compounded drug absent a specific rider. Patients using commercial insurance should request a Letter of Medical Necessity from their prescriber and submit a prior authorization before filling to avoid full out-of-pocket cost.

Cash pay pricing at most New York 503A pharmacies runs between $80 and $160 per 30-day supply at 25 mg/day, depending on the pharmacy and dose form.

Monitoring Protocol After Starting Enclomiphene in New York

Prescribers in New York follow a monitoring schedule informed by the Endocrine Society guideline and the Kim et al. trial protocol [1][3].

Weeks 4 to 6: First follow-up labs. Total testosterone, free testosterone, LH, FSH, and estradiol. The goal is total testosterone of 400 to 700 ng/dL. If estradiol exceeds 60 pg/mL and the patient is symptomatic (gynecomastia, water retention, mood changes), the prescriber may add anastrozole 0.5 mg twice weekly or reduce the enclomiphene dose to 12.5 mg [9].

Month 3: Full panel repeat including CBC to check hematocrit. Kim et al. (2016) reported no significant hematocrit elevation at 6 months with enclomiphene 12.5 mg or 25 mg compared to TRT, which raised hematocrit by a mean of 4.2 percentage points [1].

Month 6: Comprehensive review. If total testosterone remains below 350 ng/dL despite adequate enclomiphene dosing, the prescriber should reconsider the diagnosis, evaluate for occult primary hypogonadism, or discuss transitioning to testosterone replacement.

Annual monitoring: Lipid panel, PSA (men over 40), and CBC annually per AUA 2018 guideline recommendations [11].

A 2020 systematic review in Fertility and Sterility (N=791 across 11 trials) confirmed that clomiphene-class SERMs raised mean testosterone by 160 to 320 ng/dL from baseline while preserving sperm parameters, with a discontinuation rate due to adverse effects of only 4.3% [15].

How Long Until You Receive Enclomiphene Citrate in New York?

The timeline from first inquiry to receiving your medication breaks down as follows.

Days 1 to 3: Complete lab orders placed by a telehealth provider; visit a local Quest or LabCorp draw site.

Days 3 to 7: Lab results return (most panels complete within 48 to 72 hours at standard New York draw sites).

Day 7 to 9: Telehealth consultation scheduled and completed; prescription issued same day or within 24 hours if labs are in range.

Days 9 to 14: 503A pharmacy receives prescription, compounds the batch, conducts quality checks, and ships. Standard shipping within New York is 1 to 3 business days via USPS Priority or UPS Ground.

Total elapsed time from first contact to medication in hand: approximately 10 to 14 business days for most New York patients. Patients who already have recent qualifying labs (within 90 days) can shorten this to 5 to 7 business days.

Transferring an Enclomiphene Prescription to New York

Patients relocating to New York or switching to a New York-based telehealth provider can transfer an existing enclomiphene prescription under these conditions.

New York Education Law does not permit indefinite refills from an out-of-state prescriber once the patient establishes New York residency, because the prescribing physician must hold a valid New York license. A New York-licensed prescriber must review updated labs and issue a new prescription. Most telehealth platforms with a New York presence can complete this transition in 5 to 10 business days.

If the pharmacy dispensing the medication is a non-resident pharmacy, it must hold a current New York Board of Pharmacy non-resident registration. Patients can verify this on the New York Office of the Professions license lookup at op.nysed.gov before transferring [5].

Who Can Prescribe Enclomiphene Citrate in New York?

New York permits four licensed prescriber categories to write enclomiphene prescriptions:

MDs and DOs with an active New York license. No specialty restriction applies; the prescriber must document clinical appropriateness.

Nurse Practitioners (NPs) with full practice authority (FPA) granted after 2023 reforms, or those practicing under a written practice agreement with a collaborating physician. FPA NPs can prescribe independently.

Physician Assistants (PAs) practicing under a collaborative agreement with a supervising physician who holds a New York license.

Certified Midwives and CNMs do not typically manage male hypogonadism and would be outside their defined scope for enclomiphene prescribing.

The American Urological Association specifies that any prescriber initiating SERM therapy for male hypogonadism should document the off-label use, the absence of contraindications, and the patient's informed consent in the medical record [11].